Conference Description:

The role of patient engagement in gene therapy development is changing.
As the global healthcare system accelerates its acceptance of gene therapies as one-time, potentially curative, treatment options for rare diseases, the role of patient engagement in informing drug development strategy is evolving.

At this interface lies the 3rd Gene Therapy Patient Engagement Summit, uniting patient advocacy and engagement experts from leading gene therapy and gene editing drug developers, along with patient groups and patients themselves. Talks, workshops, and group discussions will shed a light on how to better integrate the patient voice into gene therapy programs at crucial stages of the drug development process.

Join us in Boston this summer to gain the actionable insights, tools, and strategies you need to better implement patient input into patient-centric gene therapy programs.

Download the full event guide to see the expert speaking faculty and content in-store for 2023, carefully co-designed with leading patient-facing figures in the field.

URL:
Tickets: https://go.evvnt.com/1546562-2?pid=154
Time: 9:00 am - 4:00 pm

Prices:
Conference + Workshop Day - Industry Rate: USD 4446.00,
Conference Only - Industry Rate: USD 2799.00,
Conference + Workshop Day - Standard Rate: USD 5446.00,
Conference Only - Standard Rate: USD 3499.00

Speakers: Alison Kujawski, Senior Outreach Manager, American Society of Cell and Gene Therapy, Amanda Rohrig, Director - Patient Advocacy, Bridge Bioscience Corp, Andrea Wilkinson, Global Head, Patient Engagement Portfolio Strategy UCB, Behtash Bahador, Director, Health Literacy, CISCRP, Brendan Hayes, Director - Education and Innovative Therapies, National Hemophilia Foundation, Brian O'Mahony, Chief Executive Officer, Irish Haemophilia Society, Craig Martin, President, Rithm Health, Daniel Leonard, Senior Director - Global Patient Advocacy, uniQure, David Rintell, Head of Patient Advocacy, Bridge Bioscience Corp, Jean-Pierre Malkowski, ED Patient Engagement Center of Excellence, Novartis AG, Jennifer Helfer, Most Recently Head Patient Advocacy and Engagement, Encoded Therapeutics, Jennifer McNary, Co-founder and Principal, Canary Advisors LLC, Jessica Riviere, Vice President - Patient Advocacy and Patient Engagement, Ultragenyx Pharmaceutical Inc, Kendall Davis, Early Development Lead, Patient Advocacy, Spark Therapeutics, Kristen Huehbner, Associate Director, Global Patient Advocacy and Engagement, BioMarin Pharmaceutical Inc., Melissa Penn, Director, Patient Engagement R and D, Bayer, Mindy Cameron, Life Sciences Consultant, AdvocacyWorks, Nan Doyle, Associate Director, Patient Insights - Rare Diseases Drug Discovery Unit, Takeda, Nicole Boice, Founder and Chief Mission Officer, Global Genes, Sara Johnson, Davis Senior Director - Patient Advocacy and Government Affair, CRISPR Therapeutics, Sujan Siva, Head of Medical Affairs and Patient Advocacy, CSL Behring, Thomas Bols, Head of Government Affairs and Public Policy, PTC Therapeutics